Genocea Biosciences Inc (NASDAQ:GNCA) Short Interest Up 25.4% in June

Genocea Biosciences Inc (NASDAQ:GNCA) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 594,300 shares, an increase of 25.4% from the May 30th total of 474,100 shares. Based on an average daily trading volume, of 767,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.3% of the company’s stock are short sold.

Genocea Biosciences stock traded down $0.13 during midday trading on Friday, reaching $3.53. The stock had a trading volume of 264,408 shares, compared to its average volume of 406,684. The company’s fifty day moving average is $4.59. Genocea Biosciences has a 1-year low of $2.24 and a 1-year high of $11.28. The stock has a market capitalization of $94.76 million, a PE ratio of -0.96 and a beta of 2.41. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 1.45.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.06). As a group, equities analysts anticipate that Genocea Biosciences will post -2.82 EPS for the current year.

In other news, major shareholder Peter W. Sonsini bought 2,857,142 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were acquired at an average price of $3.50 per share, with a total value of $9,999,997.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.33% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in Genocea Biosciences stock. Fosun International Ltd raised its stake in Genocea Biosciences Inc (NASDAQ:GNCA) by 41.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 571,028 shares of the biotechnology company’s stock after purchasing an additional 167,350 shares during the quarter. Fosun International Ltd owned approximately 0.51% of Genocea Biosciences worth $345,000 at the end of the most recent reporting period.

A number of equities research analysts recently issued reports on the company. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Finally, Stifel Nicolaus assumed coverage on AAR in a research report on Monday. They issued a “buy” rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $5.13.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Recommended Story: How interest rates affect municipal bond prices

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.